PCSK9 and familial hyperaldosteronism: Thus, FH patients with LDLR null mutations—who generally require aggressive LDL-c reduction early in life—may require prompt consideration of novel therapeutics beyond statins and PCSK9 inhibitors as well as advanced management strategies such as apheresis or liver transplantation.